A.B. Gottlieb
About
A.B. Gottlieb is a scholar working on Immunology, Rheumatology and Pathology and Forensic Medicine.
According to data from OpenAlex, A.B. Gottlieb has authored 35 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Immunology, 15 papers in Rheumatology and 8 papers in Pathology and Forensic Medicine. Recurrent topics in A.B. Gottlieb's work include Psoriasis: Treatment and Pathogenesis (23 papers), Autoimmune Bullous Skin Diseases (8 papers) and Autoimmune and Inflammatory Disorders Research (8 papers). A.B. Gottlieb is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (23 papers), Autoimmune Bullous Skin Diseases (8 papers) and Autoimmune and Inflammatory Disorders Research (8 papers). A.B. Gottlieb collaborates with scholars based in United States, Canada and United Kingdom. A.B. Gottlieb's co-authors include Baker Dg, L T Dooley, Umesh Chaudhari, Melinda Gooderham, ChiaChi Hu, Giampiero Girolomoni, Yves Poulin, C. Paul, J. Crowley and Jennifer Clay Cather and has published in prestigious journals such as The Lancet, European Heart Journal and Journal of Neurology Neurosurgery & Psychiatry.
In The Last Decade
A.B. Gottlieb
31 papers receiving 1.4k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| A.B. Gottlieb United States | 9 | 1.1k | 539 | 385 | 232 | 217 | 35 | 1.4k | ||
| Isabelle Hampele United States | 6 | 1.3k 1.2× | 751 1.4× | 344 0.9× | 217 0.9× | 261 1.2× | 8 | 1.6k | ||
| Kristina P. Callis United States | 6 | 1.2k 1.1× | 517 1.0× | 308 0.8× | 176 0.8× | 183 0.8× | 8 | 1.4k | ||
| L T Dooley United States | 5 | 1.1k 1.0× | 376 0.7× | 849 2.2× | 502 2.2× | 134 0.6× | 5 | 1.5k | ||
| Bart Frederick United States | 12 | 611 0.5× | 204 0.4× | 188 0.5× | 186 0.8× | 79 0.4× | 19 | 1.0k | ||
| Yichuan Xia United States | 4 | 637 0.6× | 338 0.6× | 156 0.4× | 99 0.4× | 108 0.5× | 6 | 892 | ||
| Andrew Pink United Kingdom | 20 | 661 0.6× | 1.5k 2.8× | 355 0.9× | 73 0.3× | 132 0.6× | 89 | 2.0k | ||
| H. Richards United States | 15 | 864 0.8× | 184 0.3× | 623 1.6× | 187 0.8× | 78 0.4× | 44 | 1.1k | ||
| Roberto Bullani Switzerland | 10 | 307 0.3× | 255 0.5× | 386 1.0× | 103 0.4× | 380 1.8× | 14 | 1.3k | ||
| Florence Ida Hsu United States | 11 | 269 0.2× | 156 0.3× | 217 0.6× | 66 0.3× | 112 0.5× | 26 | 985 | ||
| Jocelyn H. Leu United States | 17 | 553 0.5× | 90 0.2× | 612 1.6× | 376 1.6× | 56 0.3× | 45 | 1.1k |
Countries citing papers authored by A.B. Gottlieb
Since
Specialization
Citations
This map shows the geographic impact of A.B. Gottlieb's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A.B. Gottlieb with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A.B. Gottlieb more than expected).
Fields of papers citing papers by A.B. Gottlieb
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by A.B. Gottlieb. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A.B. Gottlieb. The network helps show where A.B. Gottlieb may publish in the future.
Co-authorship network of co-authors of A.B. Gottlieb
This figure shows the co-authorship network connecting the top 25 collaborators of A.B. Gottlieb. A scholar is included among the top collaborators of A.B. Gottlieb based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A.B. Gottlieb. A.B. Gottlieb is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Lebwohl, Mark, Atul Deodhar, Andrew Blauvelt, et al.. (2023). AB1097 MALIGNANCIES WITH LONG-TERM USE OF IXEKIZUMAB IN ADULTS WITH PSORIASIS, PSORIATIC ARTHRITIS, OR AXIAL SPONDYLOARTHRITIS: A POST-HOC ANALYSIS OF DATA FROM 25 RANDOMIZED CLINICAL TRIALS. 1773–1774.
2.
Merola, Joseph F., A.B. Gottlieb, Akimichi Morita, et al.. (2023). AB1089 BIMEKIZUMAB EFFICACY IN HIGH-IMPACT AREAS FOR PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS: POOLED RESULTS THROUGH TWO YEARS FROM THE BE SURE AND BE RADIANT PHASE 3 TRIALS. 1766–1767.
3.
McInnes, Iain B., R. B. M. Landewé, Philip J. Mease, et al.. (2022). LB0001 BIMEKIZUMAB IN BDMARD-NAIVE PATIENTS WITH PSORIATIC ARTHRITIS: 24-WEEK EFFICACY & SAFETY FROM BE OPTIMAL, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED, ACTIVE REFERENCE STUDY. Annals of the Rheumatic Diseases. 81. 206–207.
4.
Mease, Philip J., A.B. Gottlieb, Iain B. McInnes, et al.. (2022). POS1035 LOW RATES OF RADIOGRAPHIC PROGRESSION WITH 2 YEARS OF GUSELKUMAB, A SELECTIVE INHIBITOR OF THE INTERLEUKIN-23p19 SUBUNIT: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF BIOLOGIC-NAÏVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS. Annals of the Rheumatic Diseases. 81. 831–832.
5.
Rosmarin, David, Amit G. Pandya, Pearl Grimes, et al.. (2021). 303 Maintenance of Repigmentation After Discontinuation of Ruxolitinib Cream in Patients With Vitiligo. Journal of Investigative Dermatology. 141(10). S201–S201.
6.
Bell, Stacie, Jacqueline S. Domire, Joseph F. Merola, A.B. Gottlieb, & George Gondo. (2020). 495 The impact of psoriasis and its associated comorbidities on quality of life: Results from the National Psoriasis Foundation Annual Survey. Journal of Investigative Dermatology. 140(7). S67–S67.
7.
Poddubnyy, Denis, Filip Van den Bosch, Jürgen Braun, et al.. (2020). AB0824 WHICH PARAMETERS ARE RELEVANT IN THE IDENTIFYING AXIAL INVOLVEMENT IN PSORIATIC ARTHRITIS? – RESULTS OF A SURVEY AMONG ASAS AND GRAPPA MEMBERS. Annals of the Rheumatic Diseases. 79. 1715–1716.
8.
Gondo, George, Jacqueline S. Domire, Joseph F. Merola, A.B. Gottlieb, & Stacie Bell. (2020). 459 Understanding the impact of psoriatic disease on mental health: Results from the National Psoriasis Foundation Annual Survey. Journal of Investigative Dermatology. 140(7). S61–S61.
9.
Blauvelt, Andrew, Kim Papp, A.B. Gottlieb, et al.. (2020). A study comparing the biologic drugs ixekizumab and guselkumab for the treatment of moderate‐to‐severe plaque psoriasis. British Journal of Dermatology. 182(6).
10.
Blauvelt, Andrew, C. Paul, Peter van de Kerkhof, et al.. (2020). Long-Term Safety of Certolizumab Pegol in Plaque Psoriasis: Pooled Analysis over 3 Years from Three Phase 3, Randomized, Placebo-Controlled Studies. SKIN The Journal of Cutaneous Medicine. 4(5). s46–s46.
11.
Bell, Élaine, et al.. (2020). THU0578 ONLINE CME IMPROVES CLINICAL DECISION-MAKING IN THE MANAGEMENT OF PATIENTS WITH PSORIATIC DISEASE. Annals of the Rheumatic Diseases. 79. 530–530.
12.
Gordon, Kenneth B., Richard B. Warren, A.B. Gottlieb, et al.. (2019). Long-Term Efficacy of Certolizumab Pegol Dosed at 400 mg Every Two Weeks in Patients with Plaque Psoriasis: Pooled 128-Week Data from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2). SKIN The Journal of Cutaneous Medicine. 3. S36–S36.
13.
Coates, Laura C., et al.. (2017). SAT0461 Characterisation of different low disease activity measurements in patients with psoriatic arthritis. Annals of the Rheumatic Diseases. 76. 947–948.
14.
Kerkhof, P.C.M. van de, Lyn Guenther, A.B. Gottlieb, et al.. (2016). Ixekizumab treatment improves fingernail psoriasis in patients with moderate‐to‐severe psoriasis: results from the randomized, controlled and open‐label phases of UNCOVER ‐3. Journal of the European Academy of Dermatology and Venereology. 31(3). 477–482.
15.
Paul, C., Jennifer Clay Cather, Melinda Gooderham, et al.. (2015). Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). British Journal of Dermatology. 173(6). 1387–1399.
16.
McInnes, Iain B., Arthur Kavanaugh, A.B. Gottlieb, et al.. (2012). OP0158 Ustekinumab in patients with active psoriatic arthritis: Results of the phase 3, multicenter, double-blind, placebo-controlled psummit I study. Annals of the Rheumatic Diseases. 71. 107–107.
17.
Leonardi, C., Bruce Strober, A.B. Gottlieb, et al.. (2010). Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study.. PubMed. 9(8). 928–37.
18.
Chaudhari, Umesh, et al.. (2001). Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. The Lancet. 357(9271). 1842–1847.
19.
Gottlieb, A.B., Mark Lebwohl, Amelia Sherr, et al.. (2000). Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: Results of a pilot, multicenter, multiple-dose, placebo-controlled study. Journal of the American Academy of Dermatology. 43(4). 595–604.
20.
Gilleaudeau, Patricia, et al.. (1993). Angiotensin-converting enzyme inhibitors as possible exacerbating drugs in psoriasis. Journal of the American Academy of Dermatology. 28(3). 490–492.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Isabelle Hampele Breakdown of academic impact, for papers by Kristina P. Callis Breakdown of academic impact, for papers by L T Dooley Breakdown of academic impact, for papers by Bart Frederick Breakdown of academic impact, for papers by Yichuan Xia Breakdown of academic impact, for papers by Andrew Pink Breakdown of academic impact, for papers by H. Richards Breakdown of academic impact, for papers by Roberto Bullani Breakdown of academic impact, for papers by Florence Ida Hsu Breakdown of academic impact, for papers by Jocelyn H. Leu